Altimmune's Weight-loss Drug Shows Promising Results in Mid-stage Trial

Altimmune Inc. has reported positive results from a mid-stage trial of its experimental weight-loss drug. The drug showed potential in minimizing muscle decline while prompting fat loss, addressing a common issue faced by obesity drugmakers. More than 74% of patients’ weight loss in the trial came from fat tissue, with only 25.5% from lean mass. The company also ended a separate drug development program in hepatitis, causing a decline in shares. The statement released by Altimmune indicated that the results were similar to those achieved through diet and exercise programs. This development holds promise for addressing the obesity epidemic, a major health concern globally.